HealthDay - TUESDAY, Oct. 19 (HealthDay News) -- A small group of people with chronic myeloid leukemia (CML) who decided to stop taking the cancer drug Gleevec (imatinib) have remained cancer-free two years later, French researchers report.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.